Raytheon Company increases dividend by 8.8 percent; 14th consecutive annual increase
Get Alerts RTN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., March 21, 2018 /PRNewswire/ -- The Board of Directors of Raytheon Company (NYSE: RTN) has voted to increase the company's annual dividend payout rate by 8.8 percent, from $3.19 to $3.47 per share. The Board also authorized payment of a quarterly cash dividend of $0.8675 per outstanding share of common stock, to be paid on May 10, 2018, to shareholders of record as of the close of business on April 11, 2018. Payment of quarterly dividends is subject to Board authorization.

"With today's announcement, we have increased our annual dividend for 14 consecutive years," said Thomas A. Kennedy, Raytheon Chairman and CEO. "The dividend increase is a key part of our capital deployment strategy, and reflects our confidence in the company's growth outlook and our continued focus on creating value for shareholders."
About Raytheon
Raytheon Company, with 2017 sales of $25 billion and 64,000 employees, is a technology and innovation leader specializing in defense, civil government and cybersecurity solutions. With a history of innovation spanning 96 years, Raytheon provides state-of-the-art electronics, mission systems integration, C5I™ products and services, sensing, effects, and mission support for customers in more than 80 countries. Raytheon is headquartered in Waltham, Mass. Follow us on Twitter.
Investor Relations ContactKelsey DeBriyn+1.781.522.5141
Media ContactCorinne Kovalsky+1.781.522.5899
View original content with multimedia:http://www.prnewswire.com/news-releases/raytheon-company-increases-dividend-by-88-percent-14th-consecutive-annual-increase-300617784.html
SOURCE Raytheon Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XRP Price Prediction: Pepeto Pulls Early Buyers Even as 1,917 Whale Trades Push XRP Past $1.57
- Dean Clark Recognized Among the Best Realtors in Hoboken, NJ, With $800M+ Sold and 1,000+ Personal Sales
- InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share